STIM · Neuronetics, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · STIM

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$149.16M	$74.89M	$71.35M	$65.21M	$55.31M	$49.24M
Cost of Revenue	$76.85M	$20.73M	$19.64M	$15.48M	$11.65M	$11.55M
Gross Profit	$72.31M	$54.16M	$51.70M	$49.72M	$43.66M	$37.69M
R&D	$6.58M	$12.77M	$9.52M	$9.34M	$7.92M	$9.20M
SG&A	$49.70M	$30.32M	$25.43M	$25.52M	$25.55M	$18.24M
Total Operating Expenses	$103.74M	$88.72M	$82.26M	$84.83M	$71.22M	$60.00M
D&A	$3.46M	$2.07M	$2.01M	$1.65M	$1.06M	$941.0K
Operating Income	($31.44M)	($34.56M)	($30.55M)	($35.11M)	($27.56M)	($22.31M)
Interest Expense	$7.60M	$7.29M	$5.42M	$4.25M	$4.02M	$4.52M
Income Tax	-	-	-	-	-	-
Net Income	($39.00M)	($43.71M)	($30.19M)	($37.16M)	($31.19M)	($27.45M)
EPS - Basic	($0.59)	($1.38)	($1.05)	($1.38)	($1.46)	-
EPS - Diluted	($0.59)	($1.38)	($1.05)	($1.38)	($1.46)	-

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$28.13M	$18.46M	$59.68M	$70.34M	$94.14M	$48.96M
Accounts Receivable	$16.47M	$23.36M	$15.78M	$13.59M	$7.71M	$7.17M
Inventory	$4.33M	$4.25M	$8.09M	$8.90M	$6.56M	$3.72M
Accounts Payable	$10.74M	$11.08M	$4.75M	$2.43M	$4.30M	$3.75M
Current Assets	$61.55M	$58.12M	$93.79M	$98.77M	$115.33M	$65.01M
Total Assets	$141.55M	$140.90M	$115.83M	$116.88M	$141.22M	$78.66M
Current Liabilities	$30.52M	$31.27M	$19.81M	$33.20M	$15.70M	$13.68M
Long-term Debt	$65.81M	$55.15M	$59.28M	$22.83M	$35.34M	$34.62M
Total Liabilities	$115.31M	$109.10M	$81.64M	$59.82M	$56.05M	$53.16M
Stockholders' Equity	$22.38M	$27.71M	$34.19M	$57.06M	$85.17M	$25.49M
Retained Earnings	($458.79M)	($419.79M)	($376.08M)	($345.89M)	($308.73M)	($277.54M)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	($20.37M)	($31.00M)	($32.04M)	($30.74M)	($27.98M)	($28.39M)
Investing Cash Flow	($801.0K)	($2.41M)	($1.32M)	$6.73M	($9.84M)	($730.0K)
Financing Cash Flow	$35.85M	($6.81M)	$22.70M	$207.0K	$83.01M	$2.37M
CapEx	$801.0K	$1.47M	$2.37M	$3.27M	$2.35M	$730.0K
Free Cash Flow	($21.18M)	($32.46M)	($34.41M)	($34.01M)	($30.34M)	($29.12M)

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	48.5%	72.3%	72.5%	76.3%	78.9%	76.5%
Operating margin	-21.1%	-46.2%	-42.8%	-53.8%	-49.8%	-45.3%
EBITDA margin	-18.8%	-43.4%	-40.0%	-51.3%	-47.9%	-43.4%
Net margin	-26.1%	-58.4%	-42.3%	-57.0%	-56.4%	-55.7%
Free cash flow margin	-14.2%	-43.3%	-48.2%	-52.2%	-54.8%	-59.1%
FCF / Net income	0.54	0.74	1.14	0.92	0.97	1.06
R&D / Revenue	4.4%	17.1%	13.3%	14.3%	14.3%	18.7%
SG&A / Revenue	33.3%	40.5%	35.6%	39.1%	46.2%	37.0%
Effective tax rate	-	-	-	-	-	-
Return on assets	-27.6%	-31.0%	-26.1%	-31.8%	-22.1%	-34.9%
Return on equity	-174.3%	-157.8%	-88.3%	-65.1%	-36.6%	-107.7%
Return on invested capital	-	-	-	-	-	-
Liquidity
Current ratio	2.02	1.86	4.73	2.98	7.34	4.75
Quick ratio	1.87	1.72	4.33	2.71	6.93	4.48
Cash ratio	0.92	0.59	3.01	2.12	6.00	3.58
Leverage
Debt / Equity	2.94	1.99	1.73	0.40	0.41	1.36
Debt / Assets	0.46	0.39	0.51	0.20	0.25	0.44
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-4.1x	-4.7x	-5.6x	-8.3x	-6.9x	-4.9x
Equity multiplier	6.33	5.09	3.39	2.05	1.66	3.09
Liabilities / Assets	0.81	0.77	0.70	0.51	0.40	0.68
Efficiency
Asset turnover	1.05	0.53	0.62	0.56	0.39	0.63
Inventory turnover	17.76	4.88	2.43	1.74	1.78	3.11
Days sales outstanding	40d	114d	81d	76d	51d	53d
Days inventory outstanding	21d	75d	150d	210d	206d	118d
Days payable outstanding	51d	195d	88d	57d	135d	118d
Cash conversion cycle	10d	-6d	143d	229d	122d	52d
Valuation
P / E	-	-	-	-	-	-
P / B	4.1x	1.8x	2.4x	3.2x	1.0x	-
P / S	0.6x	0.7x	1.2x	2.8x	1.5x	-
EV / EBITDA	-	-	-	-	-	-
Growth
Revenue growth (YoY)	99.2%	5.0%	9.4%	17.9%	12.3%	21.8%
Revenue CAGR (3y)	31.8%	10.6%	13.2%	17.3%	17.3%	-
Revenue CAGR (5y)	24.8%	13.1%	15.8%	-	-	-
Gross profit growth (YoY)	33.5%	4.8%	4.0%	13.9%	15.8%	-20.3%
Operating income growth (YoY)	9.0%	-13.1%	13.0%	-27.4%	-23.6%	17.2%
Net income growth (YoY)	10.8%	-44.8%	18.8%	-19.1%	-13.6%	5.5%
EPS growth (YoY)	57.2%	-31.4%	23.9%	5.5%	-	-
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	34.8%	5.7%	-1.2%	-12.1%	-4.2%	6.9%
FCF CAGR (5y)	-	-	-	-	-	-
Book value growth (YoY)	-19.2%	-19.0%	-40.1%	-33.0%	234.1%	-46.7%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$149.16M total

Clinical Services Segment$86.98M · 58.3%

Medical Device Segment$62.18M · 41.7%

Product / service

$295.20M total

Clinic Revenue$86.98M · 29.5%

Service$86.98M · 29.5%

Product$62.18M · 21.1%

Treatment Sessions$43.32M · 14.7%

Neuro Star Advanced Therapy System$14.26M · 4.8%

Product And Service Other$1.49M · 0.5%

Geographic

$149.16M total

US$146.05M · 97.9%

Non Us$3.11M · 2.1%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

-2.14

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

4/9

Neutral

✗Net income positive
✗Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
✗Long-term debt decreased
✓Current ratio improved
✗No share dilution
✗Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Surgical & Medical Instruments & Apparatus

Company	Revenue (last FY)	Net margin	ROE
BSX	$20.07B	14.4%	12.0%
LMAT	$249.60M	23.1%	14.7%
TNDM	$1.01B	-20.2%	-131.9%
SYK	$25.12B	12.9%	14.5%
MMM	$24.95B	13.0%	69.1%

Comparing Neuronetics against the 5 most active filers in the same SIC group.